Loxo Oncology to Announce Second Quarter 2017 Financial Results

STAMFORD, Conn., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. LOXO, a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the second quarter ended June 30, 2017 on August 8, 2017 before the NASDAQ market open.

The company will not be conducting a conference call in conjunction with this earnings release.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.

Company:

Jacob S. Van Naarden

Chief Business Officer

jake@loxooncology.com 

Investors:

Peter Rahmer

The Trout Group, LLC

646-378-2973

prahmer@troutgroup.com 

Media:

Dan Budwick

1AB Media

973-271-6085

dan@1abmedia.com